Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting
MONROVIA, Calif., March 1, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that data from preclinical studies on XmAb®18087 and additional candidates deploying its XmAb® bispecific and half-life extension technology will be presented during presentations at the American Association for Cancer Research (AACR) 2017 Annual Meeting taking place April 1-5, 2017.
Abstracts are available on the AACR conference website at http://www.aacr.org. Information contained in the abstract was at the time of submission in November 2016. An updated data set will be presented at the AACR Annual Meeting in April.
Title: 3633. Anti-SSTR2 × anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors Presenter/Authors: Sung-Hyung Lee, Seung Y. Chu, Rumana Rashid, Sheryl Phung, Irene W. L. Leung, Umesh S. Muchhal, Gregory L. Moore, Matthew J. Bernett, Suzanne Schubbert, Connie Ardila, Christine Bonzon, Paul Foster, David E. Szymkowski, John R. Desjarlais. Xencor, Monrovia, CA Session: BITES Bispecifics and Checkpoints Session date and time: Tuesday, April 4, 2017, 8:00 - 12:00 PM
- Anti-SSTR2 × anti-CD3 affinity-optimized bispecific antibody produced using Xencor's bispecific platform
- The goal is to assess XmAb18087 pharmacology in cynomolgus monkeys
- T cell activation, extravasation, and cytokine induction were readily measured in peripheral blood and are indicative of SSTR2-mediated T cell activation in vivo
- Results on human cells, in mice, and in monkeys support clinical assessment of XmAb18087 in SSTR2+ cancers including neuroendocrine tumors and small cell lung cancer
Title: 1639. Combination of PD1 blockade and T cell costimulation by bispecific antibodies promotes human T cell activation and proliferation Presenter/Authors: Gregory L. Moore, Michael Hedvat, Matthew J. Bernett, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Kendra N. Avery, Rumana Rashid, Alex Nisthal, Liz Bogaert, Irene W. L. Leung, Seung Y. Chu, Umesh S. Muchhal, John R. Desjarlais. Xencor, Inc., Monrovia, CA Session: Tumor Microenvironment and Checkpoints Session date and time: Monday, April 3, 2017, 8:00 - 12:00 PM
- Bispecific antibody targeting PD1 and an undisclosed co-stimulatory receptor (PD1 x costim) produced using Xencor's bispecific platform
- Goal is to engage co-stimulatory receptors in combination with checkpoint blockade to increase T cell activation and improve patient response rate
- Compelling activity suggests clinical development is warranted for the treatment of human malignancies
Title: 1595. IL15/IL15R? heterodimeric Fc-fusions with extended half-lives Presenter/Authors: Matthew J. Bernett, Christine Bonzon, Rumana Rashid, Rajat Varma, Kendra N. Avery, Irene W. L. Leung, Seung Y. Chu, Umesh S. Muchhal, Gregory L. Moore, John R. Desjarlais. Xencor, Inc., Monrovia, CA Session: Cytokines: The First Modern Immunotherapies Session date and time: Monday, April 3, 2017, 8:00 - 12:00 PM
- IL15/IL15R? heterodimeric Fc-fusions produced using Xencor's XmAb® bispecific and half-life extension technology
- The Fc-fusions enhanced proliferation of T and NK cells in vitro and in vivo, and prolonged half-life
- Data indicate that IL15/IL15R? heterodimeric Fc-fusions demonstrate the high activity of IL15 with a more favorable PK profile
About Xencor, Inc. Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, 11 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internal programs include: XmAb5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb7195 in Phase 1 development for the treatment of asthma and allergic diseases; XmAb14045 in Phase 1 development for acute myeloid leukemia; XmAb13676 in Phase 1 development for B-cell malignancies; and XmAb18087 for the treatment of neuroendocrine tumors, in pre-clinical development. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Novartis, Amgen, MorphoSys, Merck, CSL/Janssen, Alexion and Boehringer Ingelheim. For more information, please visit www.xencor.com.
Forward Looking Statements: Statements contained in this press release and the related abstracts and presentations regarding matters that are not historical facts are forward-looking statements within the meaning of applicable securities laws, including any expectations relating to our business, research and development programs, including XmAb®18087 and other bispecific antibody candidates, partnering efforts or our capital requirements. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor's public securities filings. All forward-looking statements are based on Xencor's current information and belief as well as assumptions made by Xencor. Readers are cautioned not to place undue reliance on such statements and Xencor disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/xencor-presents-preclinical-data-on-emerging-bispecific-antibody-candidates-at-american-association-for-cancer-research-aacr-2017-annual-meeting-300415555.html
SOURCE Xencor, Inc.